药明康德 reported revenue of ¥28.90B for the period ended 2026-06-30, +38.9% year on year. Net income was ¥11.13B, a 38.5% net margin on a 53.9% gross margin. The largest revenue line is 化学业务 at 86% of the total. Free cash flow for the period was ¥4.34B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥28.90B | +38.9% |
| Gross profit | ¥15.58B | — |
| Operating income | ¥13.53B | — |
| Net income | ¥11.13B | +28.5% |
| Gross margin | 53.9% | Net margin 38.5% |
| Revenue Q/Q | +32.4% | — |
| Segment | Revenue | Share |
|---|---|---|
| 化学业务 | ¥24.99B | 86.5% |
| 测试业务 | ¥2.48B | 8.6% |
| 生物学业务 | ¥1.39B | 4.8% |
| 其他业务 | ¥0.04B | 0.1% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥13.32B | 46.1% |
| R&D | ¥0.61B | 2.1% |
| SG&A | ¥1.88B | 6.5% |
| Tax & other | ¥2.40B | 8.3% |
| Item | Amount |
|---|---|
| Total assets | ¥116.26B |
| Total liabilities | ¥32.38B |
| Shareholders' equity | ¥83.88B |
| Equity / assets | 72.2% |
| Operating cash flow | ¥6.10B |
| Capital expenditure | ¥1.77B |
| Free cash flow | ¥4.34B |
| Cash conversion (OCF / net income) | 87% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
合盛硅业 ・ 海天味业 ・ 华勤技术 ・ 今世缘 ・ 万泰生物 ・ 豪威集团 ・ 华友钴业 ・ 瑞芯微 ・ 兆易创新 ・ 洛阳钼业 ・ 德业股份 ・ 东鹏饮料
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies